The Africa Centres for Disease Control is reviewing its guidance on a coronavirus vaccine developed by AstraZeneca Plc and the University of Oxford after several European nations suspended its use amid concerns about possible adverse side effects. “The AstraZeneca vaccine was seen to be safe and efficacious and we would need to review the data. We should guide the response with strong science and evidence,” Africa CDC Director John Nkengasong said in an interview with Bloomberg TV on Tuesday. “The Africa CDC will be convening an emergency meeting this afternoon with all the experts across the continent to look at the data and what we know, and then to provide appropriate guidance to the continent.” Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process. You will be redirected to a checkout page.
To view all features and options, click here. A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.